

## **SPECIALISED COMMISSIONING - CLINICAL EVIDENCE EVALUATION CRITERIA FOR A CLINICAL COMMISSIONING POLICY STATEMENT**

URN: 1874

TITLE: Proton beam therapy for oesophageal cancer

CRG: Radiotherapy

NPOC: Cancer

Date: 20/03/19

The Panel were presented a policy proposition for not for routine commissioning.

<b>Advice</b>	<b>Conclusion of the panel</b>
<p>The Panel should provide advice on matters relating to the evidence base and policy development and prioritisation. Advice may cover:</p> <ul style="list-style-type: none"><li>• Uncertainty in the evidence base</li><li>• Challenges in the clinical interpretation and applicability of policy in clinical practice</li><li>• Challenges in ensuring policy is applied appropriately</li><li>• Issues with regard to value for money</li><li>• Likely changes in the pathway of care and therapeutic advances that may result in the need for policy review.</li></ul>	<p>The Panel has received the policy statement built upon the provided PPP and agreed that the statement is appropriately constructed to maintain the not for routine commissioning position.</p>

Report approved by:  
James Palmer  
Clinical Panel Chair  
27/03/19